{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-042962","form_type":"8-K","ticker":"IXHL","cik":"0001873875","company_name":"Incannex Healthcare Inc.","filed_at":"2025-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.322004+00:00","generated_at":"2026-05-21T10:29:38.813084+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Incannex completes Phase 2 dosing of IHL-42X for OSA; topline data expected July 2025","bullets":["Completed patient dosing in Phase 2 portion of RePOSA study on May 8, 2025; end-of-study follow-up by May 17, 2025.","Topline results from Phase 2 expected in July 2025; end-of-Phase 2 FDA meeting to follow.","Phase 3 plan: 440 patients exclusively at U.S. sites; decision supported by site and patient enthusiasm.","Incannex engaged in preliminary commercial discussions for IHL-42X ahead of data readout."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-042962","json":"https://secwatch.observer/filing/0001213900-25-042962.json","markdown":"https://secwatch.observer/filing/0001213900-25-042962.md","text":"https://secwatch.observer/filing/0001213900-25-042962.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1873875/000121390025042962/0001213900-25-042962-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1873875/000121390025042962/ea0242110-8k_incannex.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T10:29:38.813084+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}